If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
0.90    -0.046 (-5.12%)
Bid:
0.80
Ask:
1.00
Spread: 0.20 (25.00%)
Market Cap: £1.65m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

Strategic Shareholding Update

13 Apr 2026 07:00

RNS Number : 0694A
BSF Enterprise PLC
13 April 2026
 

13 April 2026

 

BSF Enterprise PLC

 

Strategic Shareholding Update

 

 

BSF Enterprise PLC (LSE: BSFA) ("BSF" or the "Company"), a leading innovator in tissue-engineered materials, is pleased to announce, further to the Company's announcement of 2 April 2026 regarding the placing of new ordinary shares (the "Placing"), that Mr John Story has acquired a significant beneficial interest in the Company pursuant to the Placing.

 

The Company understands that, following settlement, Mr Story is expected to be the largest individual shareholder. A TR-1 notification in respect of this holding is expected to be made in due course following settlement.

 

Mr Story is Chairman and a principal shareholder of Peers Hardy (UK) Limited, a well-established watch, jewellery and accessories group supplying major high street retailers and operating a portfolio of consumer brands.

 

Peers Hardy has a long track record in the design, sourcing and distribution of fashion and premium watches and accessories, including licensed and owned brands, and has demonstrated an ability to adapt to changing consumer trends within the retail and wearable technology markets.

 

The Board believes that Mr Story's experience across retail, branded consumer products and premium accessories is highly relevant to the Company's strategy as it develops its position in high-value, next-generation materials, including its recently unveiled T-Rex Leather™ product.

 

The Company looks forward to engaging with Mr Story as a supportive and strategic shareholder.

 

This announcement contains inside information for the purposes of Article 7 of Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) regulations (SI 2019/310).

 

END

 

Engage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here:

 

https://bsfenterprise.com/link/P3DZby

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Geoff Baker - Chairman

Che Connon - CEO & Director

 

We encourage all investors to share questions on this announcement via our investor website.

https://bsfenterprise.com/s/a1f22b

Bowsprit Partners

John Treacy

James Sheehan

 

 +44 (0)203 883 4430

Shard Capital (Broker)

Damon Heath

Isabella Pierre

 

(0)20 4530 6926

(0)20 4530 6928

ISIN of the Ordinary Shares

is GB00BHNBDQ51.

SEDOL Code is BHNBDQ5.

 

 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDZZGMDVGLGVZM
Date   Source Headline
21st Jan 20257:00 amRNSBSF Enterprise and Sartorius
27th Dec 20247:00 amRNSAdmission of Placing Shares
18th Dec 20247:00 amRNS3DBT Ltd Secures Prestigious Northern Accelerator
4th Dec 20247:00 amRNSOversubscribed Fundraising of £500,000
8th Nov 20247:00 amRNSPortfolio Update
26th Sep 20247:00 amRNSPortfolio Update
12th Aug 20247:00 amRNSKerato Ltd Partners with University of Montreal
18th Jun 20247:00 amRNSDirector/PDMR Shareholding
17th Jun 20247:00 amRNSDirector/PDMR Shareholding
14th Jun 202410:47 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSGrant of Options
11th Jun 20247:00 amRNSInterim Results
11th Apr 20247:00 amRNSSuccessful Cultivated Leather PoC Agreements
20th Mar 202412:56 pmRNSResult of Annual General Meeting
20th Mar 202410:19 amRNSUniversity Collaborations
14th Mar 20247:00 amRNSInvestor Evening
7th Mar 20247:00 amRNSBSF Enterprise and Ivy Farm Enter Partnership
29th Feb 20247:00 amRNSMoU with Sustainable Fashion Company
26th Feb 20247:27 amRNSNotice of AGM
22nd Feb 20247:00 amRNSKerato Limited - Update
15th Feb 20247:00 amRNSStrategic Update
31st Jan 20247:00 amRNSFull Year Results
8th Dec 20237:00 amRNSFOODTECH Joint Venture with CellRev
30th Nov 20233:07 pmRNSStandard form for notification of major holdings
24th Nov 20237:00 amRNS3D Bio-Tissues Product Partnership Progress
26th Oct 20237:00 amRNSNew Cornea Company & Investor Update
9th Oct 20239:34 amRNSParticipation in The ThinkEquity Conference
26th Sep 20232:32 pmRNSResults of General Meeting & Allotment of Shares
18th Sep 20237:00 amRNS3D Bio-Tissues receives EUR612,000 grant
11th Sep 20237:00 amRNSStrategic Update
7th Sep 20239:46 amRNSPublication of Prospectus & Notice of GM
17th Jul 20237:00 amRNSCity-Mix Bio-Pharmaceutical Update
3rd Jul 20239:56 amRNSOpens Office in Hong Kong
29th Jun 20237:00 amRNSInterim Results
23rd Jun 202311:30 amRNSCultivated Meat Approved for Consumption in US
8th Jun 20237:00 amRNSUS Investor Roadshow & Appointment of US IR Agency
1st Jun 20237:00 amRNSPublication of New Research
30th May 20237:00 amRNSSuccessful Cultivated Meat Test
25th May 20237:00 amRNSAdmittance to trading on the OTCQB Venture Market
22nd May 20237:00 amRNSCommercial Progress Update
15th May 20237:00 amRNSLab-Grown Leather Update and Innovation Award Win
21st Apr 20237:00 amRNSShowcase Meat Update
14th Apr 20238:00 amRNSAdmission of Placing Shares & Subscription Shares
12th Apr 20233:35 pmRNSUpdate to Oversubscribed £2.9 million fundraise
29th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 20237:00 amRNSOversubscribed £2.9 million fundraise
15th Mar 202311:59 amRNSResult of Annual General Meeting
15th Mar 20237:00 amRNSAGM Statement
9th Mar 20238:53 amRNSApplication for Trading on US OTCQB Venture Market
6th Mar 20237:00 amRNSCity-Mix Commercial Progress Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.